Pharma Exclusives Pressreleases
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
Wednesday, January 22, 2025Coya Therapeutics Inc a clinicalstage biotechnology company developing biologics intended to enhance regulatory T cell Treg function announces the expansion of its investigational pipeline and advancement of COYA for the treatment of inflammatory di...
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Thursday, January 16, 2025Cybin Inc a clinicalstage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative nextgeneration treatment options today announced the launch of its first strategic partnership agr...
Kindeva Drug Delivery and Emervax Partner To Bring Game Changing Vaccine Administration to Patients
Friday, January 10, 2025Kindeva Drug Delivery a global CDMO and drug delivery expert and Emervax a developer of a proprietary circular RNAbased vaccine platform emxRNATM today announced an exclusive partnership to codevelop a gamechanging solution for the administration of...
Thermo Fisher Scientific’s Olink Platform Selected for World’s Largest Human Proteome Study
Friday, January 10, 2025Thermo Fisher Scientific Inc the world leader in serving science today announced the UK Biobank Pharma Proteomics Project UKBPPP has selected its Olink Explore Platform to support the worlds largest human proteomics study of its kind UKBPPP aims to a...
Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine
Friday, January 10, 2025BioTechne a global leader in life science tools and reagents today announced the launch of new designer proteins engineered using advanced Artificial Intelligence AI based design platforms and protein evolutionary workflows This expanded portfolio fr...
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
Wednesday, January 08, 2025Biomea Fusion Inc a clinicalstage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes obesity and genetically defined cancers today announce compelling results...
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Tuesday, January 07, 2025Pfizer Inc invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla Chairman and Chief Executive Officer at the rd Annual JP Morgan Healthcare Conference on Monday January at am PST
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
Saturday, December 21, 2024Pfizer Inc announced that the US Food and Drug Administration FDA has approved BRAFTOVI encorafenib in combination with cetuximab marketed as ERBITUX and mFOLFOX fluorouracil leucovorin and oxaliplatin for the treatment of patients with metastatic c...
Bio-Techne Announces Biotherapeutic Characterization Strategic Co-marketing and Co-promotion Agreement
Friday, December 20, 2024BioTechne Corporation a leader in automated platforms for biotherapeutic characterization today announced a comarketing and copromotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterization and dev...
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
Friday, December 20, 2024Shuttle Pharmaceuticals Holdings Inc a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy RT today announced a sponsored research agreement with the Univer...
